Stock Events

Stock Events

Dyne Therapeutics 

$18.48
0
+$1.01+5.78% Today

Statistics

Day High
18.98
Day Low
18.48
52W High
-
52W Low
-
Volume
60
Avg. Volume
-
Mkt Cap
3.05B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30AprExpected
Q3 2025
Q4 2025
Next
-0.84
-0.81
-0.79
-0.76
Expected EPS
-0.772292
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-892.43MNet Income

Analyst Ratings

$37.00Average Price Target
The highest estimate is 50.00.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy
88%
Hold
13%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DYN.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap2.51B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics for rare diseases, similar to Dyne's focus on muscle diseases.
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, competing in the same space as Dyne with a focus on genetic and rare diseases.
PTC Therapeutics
PTCT
Mkt Cap5.4B
PTC Therapeutics operates in the field of genetic disorders, including Duchenne muscular dystrophy, which overlaps with Dyne's therapeutic areas.
Solid Biosciences
SLDB
Mkt Cap419.71M
Solid Biosciences is focused on treatments for Duchenne muscular dystrophy, directly competing with Dyne's muscle disease programs.
Wave Life Sciences
WVE
Mkt Cap1.44B
Wave Life Sciences is involved in designing, discovering, and developing RNA therapeutics for genetically defined diseases, competing in the same niche as Dyne.
Ultragenyx Pharmaceutical
RARE
Mkt Cap3.33B
Ultragenyx Pharmaceutical focuses on rare and ultra-rare diseases, including genetic disorders, which is a direct competition to Dyne's focus areas.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, including genetic disorders.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals is a leader in RNAi (RNA interference) therapeutics, targeting genetic diseases, which puts it in competition with Dyne.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine works on gene editing technologies, including CRISPR, to treat genetic diseases, offering an alternative approach to Dyne's RNA-focused therapies.

About

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Show more...
CEO
ISIN
US26818M1080

Listings

XNAS
US
DYN
BOATS
BOATS
DYN.BOATS

0 Comments

Share your thoughts

FAQ

What is Dyne Therapeutics stock price today?▼
The current price of DYN.BOATS is $18.48 USD — it has increased by +5.78% in the past 24 hours. Watch Dyne Therapeutics stock price performance more closely on the chart.
What is Dyne Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Dyne Therapeutics stocks are traded under the ticker DYN.BOATS.
What is Dyne Therapeutics market cap?▼
Today Dyne Therapeutics has the market capitalization of 3.05B
When is the next Dyne Therapeutics earnings date?▼
Dyne Therapeutics is going to release the next earnings report on April 30, 2026.
What were Dyne Therapeutics earnings last quarter?▼
DYN.BOATS earnings for the last quarter are -0.76 USD per share, whereas the estimation was -0.76 USD resulting in a +0.34% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Dyne Therapeutics revenue for the last year?▼
Dyne Therapeutics revenue for the last year amounts to 0 USD.
What is Dyne Therapeutics net income for the last year?▼
DYN.BOATS net income for the last year is -892.43M USD.
When did Dyne Therapeutics complete a stock split?▼
Dyne Therapeutics has not had any recent stock splits.